EPIDIOLEX® (cannabidiol) is the first in a new class of AEDs for seizures associated with LGS or Dravet syndrome in patients 2 years and older1

EPIDIOLEX is a novel AED that provides a different way to treat seizures2

  • EPIDIOLEX is the first and only FDA-approved prescription cannabidiol1
  • EPIDIOLEX is structurally distinct from other AEDs2
  • EPIDIOLEX is believed to exert its anticonvulsant effects through multiple modes of action2
  • EPIDIOLEX does not appear to exert its anticonvulsant effect through interaction with cannabinoid receptors2

EPIDIOLEX® (cannabidiol) CV Mechanism of Action Video

Discover a novel approach2

Find out how the mechanism of action of EPIDIOLEX provides a different way to treat seizures.2

EPIDIOLEX lacks euphoric effects associated with THC2

Delta-9-Tetrahydrocannabinol (THC)

Delta-9-Tetrahydrocannabinol (THC) molecule

Due to activity at the CB1 cannabinoid receptor, primarily responsible for marijuana’s euphoric effects3,4

Cannabidiol (CBD)

Cannabidiol (CBD) molecule

Very low affinity for cannabinoid receptors such as CB1 and therefore lacks euphoric side effects2